← Back to Nuqta Atlas
Editorially curated · kw-kadem-pharmacogenomics
Functional and Pharmacogenomic Characterization of Kuwaiti Metabolic Risk Variants
Functionally evaluates hallmark variants associated with anthropometric, lipid, glycemic and blood-pressure traits and adds pharmacogenomic evidence to KADEM and the planned Kuwait Variome.
01 / Project overview
What the record establishes.
- Geographic scope
- Kuwaiti population
- Project type
- Funded pharmacogenomics project
- Research domain
- Metabolic traits, diabetes and pharmacogenomics
- Years
- 2024–2029
- Lifecycle status
- active
- Status basis
- The KFAS project record marks the project active with effective dates 2024-02-01 to 2029-02-01.
- Status evidence date
- 2026-08-15
- Scale
- Starts from 85 prioritized variants in 64 genes; no new participant target stated.
02 / Organizations and population
Who and what the project connects.
- Lead organizations
- Dasman Diabetes Institute
- Partner organizations
- Kuwait Foundation for the Advancement of Sciences
- Organism / population
- Kuwaiti population genetic datasets and experimental models
03 / Data and access
What exists and how it can be reached.
Data types
- genotyping
- functional genomics
- proteomics
- pharmacogenomics
Data access
Not stated
Identifiers
No public accession or identifier is listed for this record.
04 / Evidence and provenance
Why the record is included.
Inclusion basis
Current, dated KFAS project explicitly intended to enrich population-specific variant resources.
Editorial note
Analytical child of DDI population genomics; Kuwait Variome remains an objective rather than a verified public endpoint.
Sources
- primary record source Verified 2026-08-15
Release v0.2.0